IGF-I (1-3) is a minimal N-terminal tripeptide of insulin-like growth factor I. The short motif is useful in examining initial receptor contact determinants and local charge distribution. Researchers employ it in binding studies, fragmentation mapping, and structure-based design. Its simplicity enables precise analytical and computational modeling.
CAT No: I01002
Synonyms/Alias:Gly-pro-glu; Glycyl-prolyl-glutamic acid; 32302-76-4; Glypromate; glycyl-l-prolyl-l-glutamic acid; ZYK4RVV5LS; (2S)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]pentanedioic acid; IGF-I (1-3); MFCD00144405; UNII-ZYK4RVV5LS; CHEMBL371315; SCHEMBL1170125; DTXSID80186038; CHEBI:163960; L-Glutamic acid, glycyl-L-prolyl-; Gly-Pro-Glu, >=98% (HPLC); (1-3)IGF-1; DB05633; DA-53632; HY-117483; L-Glutamic acid, N-(1-glycyl-L-prolyl)-; CS-0066182; NS00069173; (1-3)-HUMAN INSULIN-LIKE GROWTH FACTOR I; BRD-K83502127-001-01-6
3. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
4. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
5. TMEM16F and dynamins control expansive plasma membrane reservoirs
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More